Aducanumab has shown promise in reducing abnormal brain proteins linked to Alzheimer’s and is in the press recently. The monoclonal antibody, Aducanumab, binds to aggregates of amyloid beta including fibrils, oligomers, decamers, etc., but does not bind much to soluble amyloid. Aducanumab was found by screening healthy elderly individuals who did not have Alzheimer's disease for antibodies that could be protective. It seems that Aducanumab is very potent and selective antibody. So although antibodies don't cross the blood brain barrier very readily, some of it does. So a potent and selective antibody can still have some therapeutic value if a little bit crosses the BBB. Here's a little more background on Aducanumab.

They do state in their Nature study that "the brain:plasma AUC ratio of 1.3% was higher than the 0.1% frequently reported for systemically administered antibodies." So Aducanumab apparently does naturally cross the BBB better than many other reported antibodies. However, Transcendpep (Mtfp) would likely result in a dramatic increase in the brain penetration of Aducanumab. An application of Mtfp would likely improve efficacy and allow for a lower dose to be used.

BearDownAZ